City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
Filters
Save & Share
Clear Filters
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
MDS Centers of Excellence
Accepting patients
REM-422
A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
Learn more- MYB mRNA Degrader
- Phase 1
Accepting patients
ACCESS
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
Learn more- Allogeneic Stem Cell Transplant
- Pre-Transplant
- Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
OPTIMIZE
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Learn more- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
GLB-001
A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Learn more- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
- High Risk
- Phase 1
Accepting patients
BTX-A51
A First-In-Human, Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX-A51 Capsules Alone and in Combination With Azacitidine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Learn more- CK1-Alpha Inhibitor
- Phase 1
- Has results
Not yet accepting
S227928
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
Learn more- Antibody Drug Conjugate (ADC)
- MCL-1 Inhibitor
- CD74
- Phase 1/2
Accepting patients
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Learn more- Allogeneic Stem Cell Transplant
- Phase 1
Accepting patients
BEXMAB
A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia
Learn more- BCL-2 Inhibitor
- Monoclonal Antibody
- Clever-1
- Phase 1/2
- Has results
Accepting patients
KER-050
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Learn more- Growth Factor
- Phase 2
- Has results
Not currently accepting
A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)
Learn more- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
- Phase 1/2